Literature DB >> 10763917

Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase.

K Nakanishi1, J Fujimoto, T Ueki, K Kishimoto, T Hashimoto-Tamaoki, J Furuyama, T Itoh, Y Sasaki, E Okamoto.   

Abstract

Hepatocyte growth factor (HGF) is known to be a potent mitogen and motogen for epithelial cells. Hepatocellular carcinoma (HCC) often metastasizes, and the c-Met/HGF receptor is highly expressed by HCC cells. The aim of this study was to investigate the signaling pathways associated with the motogenic effect of HGF on HCC cells via c-Met. HCC cell lines (Hep3B, HepG2, PLC, and Huh-7) and HCC cells harvested from patients were used for the Boyden chamber assay of chemotactic activity as well as for immunoprecipitation and immunoblotting studies. HGF stimulated the motility of Hep3B, HepG2, and Huh-7 cells in a dose-dependent manner in association with tyrosine phosphorylation of c-Met and activation of phosphatidylinositol 3-kinase (PI3-K). A tyrosine kinase inhibitor (genistein) and a PI3-K inhibitor (wortmannin) prevented the migration of HCC cells. However, migration was not prevented by calphostin C, an inhibitor of protein kinase C (PKC), which is a downstream target of phospholipase Cgamma (PLCgamma). HGF also stimulated the migration of HCC cells obtained from three patients, while wortmannin prevented the migration of these cells. These results indicate that HGF stimulates the migration of HCC cells through the tyrosine phosphorylation of c-Met via activation of PI3-K.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10763917     DOI: 10.1023/a:1006685218766

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  36 in total

Review 1.  Protein modules and signalling networks.

Authors:  T Pawson
Journal:  Nature       Date:  1995-02-16       Impact factor: 49.962

2.  Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase.

Authors:  M Amano; K Chihara; K Kimura; Y Fukata; N Nakamura; Y Matsuura; K Kaibuchi
Journal:  Science       Date:  1997-02-28       Impact factor: 47.728

3.  Hepatocyte growth factor gene therapy of liver cirrhosis in rats.

Authors:  T Ueki; Y Kaneda; H Tsutsui; K Nakanishi; Y Sawa; R Morishita; K Matsumoto; T Nakamura; H Takahashi; E Okamoto; J Fujimoto
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

4.  The pathway to signal achievement.

Authors:  S E Egan; R A Weinberg
Journal:  Nature       Date:  1993-10-28       Impact factor: 49.962

5.  Genistein, a specific inhibitor of tyrosine-specific protein kinases.

Authors:  T Akiyama; J Ishida; S Nakagawa; H Ogawara; S Watanabe; N Itoh; M Shibuya; Y Fukami
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

6.  Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.

Authors:  G A Rodrigues; M Park
Journal:  Oncogene       Date:  1994-07       Impact factor: 9.867

7.  Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model.

Authors:  E Santoni-Rugiu; K H Preisegger; A Kiss; T Audolfsson; G Shiota; E V Schmidt; S S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

8.  Hepatocyte growth factor in transgenic mice: effects on hepatocyte growth, liver regeneration and gene expression.

Authors:  G Shiota; T C Wang; T Nakamura; E V Schmidt
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

9.  Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement.

Authors:  E Gherardi; J Gray; M Stoker; M Perryman; R Furlong
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

10.  Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells.

Authors:  K Matsumoto; K Matsumoto; T Nakamura; R H Kramer
Journal:  J Biol Chem       Date:  1994-12-16       Impact factor: 5.157

View more
  12 in total

1.  PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Authors:  Roberto Gedaly; Paul Angulo; Jonathan Hundley; Michael F Daily; Changguo Chen; Alvaro Koch; B Mark Evers
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

2.  Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma.

Authors:  Gregory A Watson; Xinglu Zhang; Michael T Stang; Ryan M Levy; Pierre E Queiroz de Oliveira; William E Gooding; James G Christensen; Steven J Hughes
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

3.  Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion.

Authors:  Wei Ding; Hanning You; Hien Dang; Francis LeBlanc; Vivian Galicia; Shelly C Lu; Bangyan Stiles; C Bart Rountree
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 4.  Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity.

Authors:  Tomoko Aoki; Naoshi Nishida; Masatoshi Kudo
Journal:  J Histochem Cytochem       Date:  2021-11-09       Impact factor: 2.479

5.  Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.

Authors:  H Reynaert; K Rombouts; A Vandermonde; D Urbain; U Kumar; P Bioulac-Sage; M Pinzani; J Rosenbaum; A Geerts
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 6.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

7.  Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.

Authors:  Alok R Singh; Shweta Joshi; Adam M Burgoyne; Jason K Sicklick; Sadakatsu Ikeda; Yuko Kono; Joseph R Garlich; Guillermo A Morales; Donald L Durden
Journal:  Mol Cancer Ther       Date:  2016-08-05       Impact factor: 6.261

8.  Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin.

Authors:  Matthew H Herynk; Rachael Tsan; Robert Radinsky; Gary E Gallick
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

9.  PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma.

Authors:  Xin He; Zhenqi Zhu; Carla Johnson; John Stoops; Amanda E Eaker; William Bowen; Marie C DeFrances
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

10.  Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas.

Authors:  C Holgren; U Dougherty; F Edwin; D Cerasi; I Taylor; A Fichera; L Joseph; M Bissonnette; S Khare
Journal:  Oncogene       Date:  2010-07-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.